Bio-Techne Corp (TECH)
Bio-Techne Corp is a healthcare company listed on NASDAQ as common stock under the ticker TECH. Through its subsidiaries, the company develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing customers worldwide. Its operations are organized into two segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment focuses on biological reagents and related tools used in life science research, diagnostics, and cell and gene therapy, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. It also provides protein analysis instruments and immunoassays used in automated western blot and multiplexed ELISA workflows. The Diagnostics and Genomics segment develops diagnostic products such as controls, calibrators, assays, exosome-based molecular diagnostics, tissue-based in-situ hybridization assays, and genetic and oncology kits. The company, formerly known as Techne Corporation, adopted the Bio-Techne name in 2014 and is headquartered in Minneapolis, Minnesota.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TECH
|
$68.95
|
-4.7% Downside
|
Fair
|
$70.73
|
-2.2% Downside
|
Fair
|
Good
|
0.4%
|
November 3, 2026
|
62.4x
|
5.4x
|
9.3x
|
11.343 B
|
11.12 B
|
2.5%
|
99.6%
|
17.6
|
27.4%
|
144.8%
|
